Constellium SE $CSTM Shares Sold by Charles Schwab Investment Management Inc.

Key Points

• Charles Schwab Investment Management Inc. reduced its stake in Constellium SE by 20.3%, now owning approximately 0.52% of the company worth $7.4 million after selling 187,266 shares.
• In the first quarter, other institutional investors also made significant changes, with GAMMA Investing LLC increasing its stake by 2,485.6%, while US Bancorp DE raised its position by 1,034.7%.
• Constellium's stock opened at $14.57, experiencing a 1.9% increase, with earnings results reflecting a miss against analysts' expectations, reporting $0.25 EPS versus a consensus of $0.28.

Charles Schwab Investment Management Inc. reduced its position in Constellium SE (NYSE:CSTM - Free Report) by 20.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 736,878 shares of the industrial products company's stock after selling 187,266 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.52% of Constellium worth $7,435,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in CSTM. GAMMA Investing LLC lifted its stake in shares of Constellium by 2,485.6% in the 1st quarter. GAMMA Investing LLC now owns 2,689 shares of the industrial products company's stock valued at $27,000 after purchasing an additional 2,585 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in Constellium during the first quarter valued at approximately $38,000. Parallel Advisors LLC grew its stake in Constellium by 519.2% during the first quarter. Parallel Advisors LLC now owns 4,941 shares of the industrial products company's stock worth $50,000 after buying an additional 4,143 shares during the period. US Bancorp DE increased its position in shares of Constellium by 1,034.7% in the first quarter. US Bancorp DE now owns 5,163 shares of the industrial products company's stock worth $52,000 after acquiring an additional 4,708 shares in the last quarter. Finally, Signaturefd LLC raised its stake in shares of Constellium by 20.3% in the 1st quarter. Signaturefd LLC now owns 6,002 shares of the industrial products company's stock valued at $61,000 after acquiring an additional 1,013 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Constellium Stock Up 1.9%

Shares of Constellium stock opened at $14.57 on Wednesday. The company has a fifty day moving average price of $13.86 and a 200 day moving average price of $11.89. The company has a current ratio of 1.23, a quick ratio of 0.53 and a debt-to-equity ratio of 2.47. Constellium SE has a twelve month low of $7.32 and a twelve month high of $17.27. The stock has a market cap of $2.03 billion, a price-to-earnings ratio of 76.67 and a beta of 1.69.

Constellium (NYSE:CSTM - Get Free Report) last posted its earnings results on Tuesday, July 29th. The industrial products company reported $0.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.03). The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.08 billion. Constellium had a net margin of 0.37% and a return on equity of 3.43%. Equities research analysts forecast that Constellium SE will post 1.1 earnings per share for the current fiscal year.

About Constellium

Constellium SE, together with its subsidiaries, engages in the design, manufacture, and sale of rolled and extruded aluminum products for the packaging, aerospace, automotive, defense, and other transportation and industry end-markets. The company operates through three segments: Packaging & Automotive Rolled Products, Aerospace & Transportation, and Automotive Structures & Industry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.